title: In vitro activity of BAL30072 against Burkholderia pseudomallei.
abstract: Burkholderia pseudomallei is an intrinsically antibiotic-resistant Category B priority pathogen and the aetiological agent of melioidosis. Treatment of B. pseudomallei infection is biphasic and lengthy in order to combat the acute and chronic phases of the disease. Acute-phase treatment preferably involves an intravenous cephalosporin (ceftazidime) or a carbapenem (imipenem or meropenem). In this study, the anti-B. pseudomallei efficacy of a new monosulfactam, BAL30072, was tested against laboratory strains 1026b and 1710b and several isogenic mutant derivatives as well as a collection of clinical and environmental B. pseudomallei strains from Thailand. More than 93% of the isolates had minimal inhibitory concentrations (MICs) in the range 0.004-0.016 μg/mL. For the laboratory strain 1026b, the MIC of BAL30072 was 0.008 μg/mL, comparable with the MICs of 1.5 μg/mL for ceftazidime, 0.5 μg/mL for imipenem and 1 μg/mL for meropenem. Time-kill curves revealed that BAL30072 was rapidly bactericidal, killing >99% of bacteria in 2 h. BAL30072 activity was not significantly affected by efflux, it was only a marginal substrate of PenA β-lactamase, and activity was independent of malleobactin production and transport and the ability to transport pyochelin. In summary, BAL30072 has superior in vitro activity against B. pseudomallei compared with ceftazidime, meropenem or imipenem and it is rapidly bactericidal.
authors: Department of Microbiology, Immunology and Pathology, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University, Fort Collins, CO 80523-0922, USA.
authors: Takehiko
authors: T
authors: Mima
authors: Brian H
authors: BH
authors: Kvitko
authors: Drew A
authors: DA
authors: Rholl
authors: Malcolm G P
authors: MG
authors: Page
authors: Eric
authors: E
authors: Desarbre
authors: Herbert P
authors: HP
authors: Schweizer
references: J Bacteriol. 1997 Apr;179(7):2116-25
references: 9079894
references: Antimicrob Agents Chemother. 1991 Aug;35(8):1635-40
references: 1718214
references: Antimicrob Agents Chemother. 2010 Aug;54(8):3113-20
references: 20498323
references: Expert Rev Anti Infect Ther. 2006 Jun;4(3):445-55
references: 16771621
references: PLoS Negl Trop Dis. 2009 Sep 22;3(9):e519
references: 19771149
references: J Antimicrob Chemother. 2010 Feb;65(2):266-70
references: 19996139
references: Proc Natl Acad Sci U S A. 1981 Jul;78(7):4256-60
references: 6794030
references: J Bacteriol. 2006 Feb;188(4):1551-66
references: 16452439
references: Nat Rev Microbiol. 2006 Apr;4(4):272-82
references: 16541135
references: Antimicrob Agents Chemother. 1999 Mar;43(3):465-70
references: 10049252
references: Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302
references: 20308379
references: Clin Microbiol Rev. 2005 Apr;18(2):383-416
references: 15831829
references: Antimicrob Agents Chemother. 2003 Jul;47(7):2082-7
references: 12821450